Q/c Technologies, Inc. (QCLS)

Price$1.79Cached quote
QCLSNasdaq
Loading local price history

Financial charts

Revenue

Net income

Total cash / debt

CashTotal debt

Financial statements

13 annual periodsNewest to oldest
2025202420232022202120202019201820172016201520142013
Revenue$0$0$0$0——$1.6M$1.7M$3.4M$3.0M$2.1M$4.4M$3.6M
Gross profit$0$0$0$0——$478,747$127,285$948,580$1.9M$1.2M$3.3M$1.7M
Gross margin——————30.36%7.64%28.28%63.42%55.05%73.45%46.51%
Research & development$3.5M$3.4M$7.9M$9.1M$6.7M$2.5M$276,788$1.1M$1.3M$1.2M$1.4M$916,308$1.0M
Operating expenses$9.6M$8.7M$16.4M$15.3M——$4.0M$10.2M$7.6M$5.2M$10.8M$6.5M$3.5M
Operating income−$9.8M−$10.2M−$17.1M−$15.3M−$28.8M−$9.5M−$3.5M−$10.1M−$6.6M−$3.3M−$9.7M−$3.2M−$1.8M
Operating margin——————−220.17%−604.02%−197.15%−112.42%−457.78%−72.37%−50.61%
EBITDA−$9.6M−$8.7M−$16.4M−$15.3M—−$9.5M−$3.4M−$9.8M−$6.4M−$3.0M−$9.4M−$2.9M−$1.5M
EBITDA margin——————−215.47%−589.94%−189.70%−102.75%−443.59%−64.48%−40.70%
Net income−$11.6M−$23.4M−$4.0M−$15.2M−$29.9M−$9.5M−$3.9M−$10.8M−$7.4M−$3.3M−$9.3M−$3.1M−$1.5M
Net profit margin——————−246.55%−651.37%−219.58%−111.57%−440.27%−70.99%−42.67%
Basic EPSper basic share-$8.66-$1,092.70-$522.34-$1,150.52-$2,499.00-$14,641.20-$37,338.00-$131,006.40-$850,659.60-$659,971.20-$1,958,275.20-$714,067.20-$1,038,643.20
Diluted EPSper diluted share-$8.66-$1,092.70-$522.34-$1,150.52—-$14,641.20-$37,338.00-$131,006.40-$850,659.60-$659,971.20-$1,958,275.20-$714,067.20-$1,038,643.20

Owners

Reported shareholders

Reference date Jun 30, 2026
Voss Chelsea Sierra · ≈3.68% of listed sharesSilverman Joshua · ≈3.20% of listed sharesQuinn Opportunity Partners LLC · 1.50% of listed sharesVANGUARD CAPITAL MANAGEMENT LLC · 1.40% of listed sharesJANE STREET GROUP, LLC · 1.07% of listed sharesGEODE CAPITAL MANAGEMENT, LLC · 0.86% of listed sharesUBS Group AG · 0.72% of listed sharesBalyasny Asset Management L.P. · 0.70% of listed sharesHRT FINANCIAL LP · 0.62% of listed sharesADAR1 Capital Management, LLC · 0.61% of listed sharesVANGUARD FIDUCIARY TRUST CO · 0.53% of listed sharesSTATE STREET CORP · 0.31% of listed sharesWhite Billy Joe · ≈0.31% of listed sharesBernstein Bruce · ≈0.31% of listed sharesFriscia Stephen · ≈0.31% of listed sharesDIMENSIONAL FUND ADVISORS LP · 0.23% of listed sharesNORTHERN TRUST CORP · 0.22% of listed sharesPEAK6 LLC · 0.16% of listed sharesRAUCH GARY M · ≈0.15% of listed sharesGlass Mitchell · ≈0.15% of listed shares
≈3.68%of listed shares
Voss Chelsea Sierra301.46K shares · Mar 30, 2026
View holders
Top 20 reported holders of QCLS
Holder% owned
Voss Chelsea Sierra
≈3.68%301.46K shares
Silverman Joshua
≈3.20%262.19K shares
Quinn Opportunity Partners LLC
1.50%123.02K shares
VANGUARD CAPITAL MANAGEMENT LLC
1.40%115.03K shares
JANE STREET GROUP, LLC
1.07%87.24K shares
GEODE CAPITAL MANAGEMENT, LLC
0.86%70.68K shares
UBS Group AG
0.72%58.89K shares
Balyasny Asset Management L.P.
0.70%57.69K shares
HRT FINANCIAL LP
0.62%50.37K shares
ADAR1 Capital Management, LLC
0.61%50K shares
VANGUARD FIDUCIARY TRUST CO
0.53%43.05K shares
STATE STREET CORP
0.31%25.31K shares
White Billy Joe
≈0.31%25.02K shares
Bernstein Bruce
≈0.31%25K shares
Friscia Stephen
≈0.31%25K shares
DIMENSIONAL FUND ADVISORS LP
0.23%19.06K shares
NORTHERN TRUST CORP
0.22%18K shares
PEAK6 LLC
0.16%12.78K shares
RAUCH GARY M
≈0.15%12.5K shares
Glass Mitchell
≈0.15%12.5K shares

Percentages use 8.19M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.

Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.

Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026
Buys3$5.5K disclosed value
Sells (SEC code S)0$0.00 disclosed value
3 recent transactions
TransactionInsiderTypeSharesPriceValueOwned after
Mar 30, 2026Form 4Voss Chelsea SierraDirectorBuyCommon stock · indirect1.8K$3.15$5.5K61.6K
Nov 14, 2025Form 4PharmaCyte Biotech, Inc.TenPercentOwnerBuyWarrants · derivative889.9K——889.9K
Sep 4, 2025Form 4PharmaCyte Biotech, Inc.TenPercentOwnerBuySeries H Convertible Preferred Stock · derivative889.9K——889.9K

Community posts

It’s quiet here.

No posts about QCLS yet. Start the conversation.

Write the first post